Breast cancer chemotherapy is the major therapeutic weapon in the fight against this disease across the Maghreb. With 78.5% of Moroccan patients and 74.6% of Tunisian patients benefiting from it, this revolutionary treatment is transforming the prognosis of thousands of women facing this ordeal.
Understanding chemotherapy: a tailor-made treatment
Before or after surgery: a personalised strategy
Chemotherapy acts as a treatment complementary to breast surgery. This systemic therapy can precede the operation — in which case it is called neoadjuvant chemotherapy — or follow it to eliminate residual cancer cells.
Main objective: to reach all malignant cells, even those invisible to examinations, thereby reducing the risk of recurrence by 5 to more than 50% depending on the situation.
An individualised approach in the Maghreb
In Tunisia, therapeutic protocols are meticulously adapted to each patient. The choice depends on:
- Overall state of health
- The type and grade of the cancer
- The stage of the tumour's progression
- The response to treatment
In Algeria, despite infrastructure challenges, the opening of four new centres in 2019 has considerably improved access to chemotherapy care.
Precise indications: when should chemotherapy be prescribed?
For invasive cancers: preventing and curing
Neoadjuvant chemotherapy aims to reduce the size of the tumour, often making conservative surgery possible rather than a mastectomy. This approach is particularly beneficial for young women.
Criteria for post-operative indication:
- Diagnosis before the age of 35
- Confirmed lymph-node involvement
- Large tumour size
- High cancer grade
- HER2 overexpression without hormone receptors
Metastatic cancers: stabilising and supporting
For metastases, chemotherapy is often combined with hormone therapy or targeted therapies. The objective then becomes controlling the progression and improving quality of life.
Major innovation: Systematic tumour sequencing now triples progression-free survival, revolutionising personalised care.
Meticulous preparation: before each session
A rigorous pre-treatment assessment
The oncologist scrupulously assesses the patient's general condition before each cycle. This monitoring includes:
- Checking weight and blood pressure
- Assessing fatigue and morale
- A complete blood count (platelets, white and red blood cells)
In Morocco, the average waiting time for access to neoadjuvant chemotherapy is 51.1 days, compared with 83.7 days for post-operative chemotherapy.
Implantable port: safety and comfort
This small device, placed under the skin of the chest, protects fragile veins during repeated infusions. This minor surgical innovation avoids skin complications and greatly facilitates care.
Therapeutic protocols: a cutting-edge arsenal
Optimal schedule: between efficacy and recovery
Sessions follow a precise rhythm with essential rest periods. Generally, 4 to 6 cycles spaced 3 weeks apart make up a complete treatment, spread over 3 to 6 months.
In Tunisia, adjuvant protocols favour:
- Anthracyclines alone: 23.7% of cases
- Sequential (anthracyclines + taxanes): 51.7% of cases
- Taxanes alone: 5.2% of cases
Cytotoxic drugs: surgical precision
These molecules act on cell division, specifically targeting the reproduction mechanisms of cancerous DNA.
Main families:
Anthracyclines: Doxorubicin and epirubicin, formidable but requiring cardiac monitoring. Taxanes: Paclitaxel and docetaxel, effective but often causing complete alopecia. Antipyrimidines: 5-fluorouracil and capecitabine, sometimes responsible for hand-foot syndrome. Alkylating agents: Cyclophosphamide, frequently combined with other molecules.
| Family | Molecules | Point to watch |
|---|---|---|
| Anthracyclines | Doxorubicin, epirubicin | Cardiac monitoring |
| Taxanes | Paclitaxel, docetaxel | Complete alopecia |
| Antipyrimidines | 5-fluorouracil, capecitabine | Hand-foot syndrome |
| Alkylating agents | Cyclophosphamide | Frequently combined with other molecules |
Recent therapeutic innovations
Triple-negative cancers now benefit from revolutionary treatments such as Trodelvy® and Keytruda®, raising median survival from 16 to 23 months.
Side effects: anticipating to manage better
Predictable and temporary manifestations
Chemotherapy affects rapidly dividing cells: hair, nails, mucous membranes and blood cells.
Most frequent effects:
Alopecia: Gradual, beginning 2-3 weeks after the first infusion. Hair grows back 6-8 weeks after the end of treatment.
Digestive disorders: Anticipatory nausea linked to anxiety, effectively controlled by modern antiemetics.
Skin changes: Dryness, hand-foot syndrome with capecitabine, temporary nail changes.
Crucial haematological monitoring
The drop in blood cells requires constant vigilance:
- Leukopenia: Increased risk of infection
- Neutropenia: Critical point between the 8th and 12th day
- Anaemia: Intense fatigue
- Thrombocytopenia: Coagulation disorders
Caution: Any fever, even a mild one, constitutes a medical emergency in a patient undergoing chemotherapy.
Costs and access in the Maghreb
Contrasting economic realities
In Morocco, a chemotherapy cycle costs 1,000 dirhams per session according to the National Reference Pricing, with reimbursement of 90-100% for covered patients.
In Tunisia, the overall cost can reach 18,500 US dollars for a complete treatment, but public facilities offer very affordable rates.
In Algeria, despite theoretical coverage, drug stock shortages pose major challenges, sometimes forcing patients to interrupt their treatment.
Organisational innovations
The trial of home tele-monitoring for oral anticancer drugs is revolutionising care, offering more comfort while maintaining therapeutic safety.
Support and quality of life
Essential psychological support
Anticipatory nausea, linked to anxiety, requires comprehensive care combining medication and psychological support.
Adapted physical activity
Contrary to popular belief, keeping up regular physical activity during chemotherapy effectively combats fatigue and improves tolerance to treatment.
Drug interactions: vigilance required
Dietary supplements based on curcumin or quercetin, however appealing, can compromise the efficacy of chemotherapy. A specialist consultation is essential before any self-medication.
Looking ahead: towards precision medicine
Personalised medicine is gradually transforming breast cancer chemotherapy. Genomic tests now make it possible to identify the patients who will benefit most from these heavy treatments, avoiding unnecessary therapies.
In the Maghreb, the constant improvement of infrastructure, the ongoing training of care teams and gradual access to therapeutic innovations are shaping a more promising future. Every chemotherapy session represents one more step towards recovery, driven by the growing expertise of regional medical teams.
Chemotherapy, despite its constraints, remains today one of the most effective weapons against breast cancer. With suitable medical care and solid family support, it makes it possible to face the future with confidence, paving the way towards remission and a return to a normal life.
